Background Clinical penetrance of hereditary hemochromatosis is highly variable. We hypothesized that it might be modified by factors involved in the cellular immune response, such as toll-like receptors (TLRs) or nucleotide oligomerization domain proteins (NODs).
Methods Clinical expression of hemochromatosis was assessed as a function of TLR4, TLR9, and NOD2 polymorphisms in 99 homozygous carriers of the HFE C282Y mutation with mild-to-severe iron overload.
Results Thirteen (13%) of the 99 hemochromatosis patients were heterozygous for a TLR4 Asp299Gly polymorphism and 86 (87%) were TLR4 wild-type-only carriers. Clinical expression of hemochromatosis was observed more frequently in carriers of the TLR4 polymorphism (100%) than in TLR4 wild-type carriers (56%, P = 0.002). This was based on higher prevalences of liver disease (92 vs. 45%, P = 0.002) and arthropathy of metacarpophalangeal joints (69 vs. 35%, P = 0.018) in TLR4 polymorphism carriers. The finding was strengthened by the strong association of TLR4 polymorphism with liver fibrosis in the subgroup of 52 patients who underwent a liver biopsy (P = 0.011). The TLR4 polymorphism did, however, not correlate with body iron overload. The study results remained significant in multiple regression analyses after excluding possible confounding effects, such as age, sex, alcohol, or meat intake, and in the subgroup of 84 patients presenting as the first members of their families. 
Introduction
In the USA and central Europe, about 90% of patients with typical clinical features of hemochromatosis are homozygous for a C282Y mutation of the HFE gene [1, 2] . Main clinical manifestations are hepatic fibrosis and painful arthropathies, further rare manifestations are secondary diabetes mellitus, cardiopathy, and hypogonadism. Epidemiological studies indicate, however, a highly variable clinical penetrance of the homozygous HFE C282Y mutation [3] [4] [5] . Thus, a possible role of further genetic and/or environmental factors modifying phenotypic expression of the homozygous HFE C282Y genotype must be postulated.
Clinical manifestations of hereditary hemochromatosis derive from body iron overload going along with toxic effects of iron accumulated in tissues. Such iron generates free oxyradicals that exceeds the capacity of the cytoprotective system of the cells and leads to alteration of proteins, membrane lipids, and even nucleic acids. The accompanying inflammatory reaction contributes to substantial tissue damage.
The toll-like receptors (TLRs) serve as pattern-recognition receptors at a proximal step in the innate immune response to microbial pathogens [6] . Extracellular TLR4 is specifically involved in the recognition of bacterial lipopolysaccharide as well as reactive oxygen species, signalling of which activates the nuclear factor-kB (NF-kB). This is a transcription factor involved in the regulation of the expression of cytokines and other mediators that participate in the inflammatory response of the cells [7, 8] . NF-kB is further activated by intracellular TLR9 and the nucleotide oligomerization domain protein, NOD2 [9, 10] . Earlier reports have shown synergistic effects of TLR4, TLR9, and NOD2 in the cellular immune response [11, 12] . There are well-characterized polymorphisms in all these genes, which were shown to be associated with clinical expression of inflammatory diseases, such as septic shock with gram-negative microorganisms (TLR4), Crohn's disease (TLR9 and NOD2), and atherosclerosis (TLR4; see Refs [13] [14] [15] [16] [17] ). Designing this study, we hypothesized that one or several of these receptors might modify the clinical expression of hereditary hemochromatosis influencing the immune response to oxyradicals generated on the basis of iron overload.
Patients and methods

Study design
This retrospective association study included 99 patients homozygous for the C282Y mutation of the HFE gene and investigated a possible influence of TLR4, TLR9, and NOD2 polymorphisms on clinical expression of hereditary hemochromatosis.
Study patients
Approval for this project was obtained from the Ethics Committee of the University Hospital of Zurich. Patients with homozygous C282Y mutation of the HFE gene were enrolled. They presented with clinical manifestation(s) of hemochromatosis, were evaluated for elevated serum ferritin concentrations, or were contacted on the basis of family screening. All patients included gave written informed consent to participate in the study. Exclusion criteria were chronic hepatitis B or C virus infection, actual or previous treatment with deferoxamine, and blood donation before hemochromatosis was diagnosed. Clinical parameters, histological findings, laboratory results, and the amount of iron removed by phlebotomy were assessed by the patients' history and from their medical records.
Evaluations were performed including all study patients as well as including exclusively the 84 patients presenting as the first members of their families (index patients), that is, patients recruited on the basis of family screening were excluded from the latter analysis. Part of the patients had been included in earlier studies investigating the iron isotopic composition of blood [18] and the influence of tumor necrosis factor (TNF)-a G-308A polymorphism on iron accumulation [19] in patients with hereditary hemochromatosis.
Assessment of clinical and biochemical parameters
Study physicians consulted patients and their medical records assessing age, serum ferritin, and clinical manifestations at the time when hemochromatosis was diagnosed. Liver disease was assumed to be present, if histological examination showed substantial portal fibrosis and/or septal/bridging fibrosis or cirrhosis [20] or, in patients without liver biopsy, if serum concentration of alanine transaminase (ALT) was elevated at the time of diagnosis. Results of histological examination of liver tissue were available in 52 patients, results of quantitative determination of iron concentration in 29 patients. Hepatic iron index was calculated as iron concentration of dry liver tissue (mmol/g) divided by years of age. All patients with liver disease were tested for hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibodies (anti-HBc) and hepatitis C virus antibodies (anti-HCV). Body iron overload was assessed as the total amount of iron removed to achieve a serum ferritin concentration of less than 300 mg/l. The amount of iron removed was calculated assuming that a unit of 500 ml blood contains 250 mg of elemental iron [21] . Study physicians assessed meat and alcohol intake as long-term habit patterns by interviewing the patients using a standardized questionnaire. Meat intake was assessed as the number of meat meals and the amount of meat consumed per week. Considerable meat intake was defined as either at least 5 meat meals or at least 500 g meat taken in per week. Alcohol intake was calculated from the amount of beer, wine, and liquor consumed weekly, assuming an alcohol content of 4, 12, and 20%, respectively. Considerable alcohol intake was defined as consumption of at least 140 g (males) or at least 70 g (females) alcohol per week.
Genetic analyses
Blood was obtained in 5 ml EDTA Vacutainer (Beckton Dickinson, Allschwil, Switzerland) tubes. DNA was isolated by a standard rapid lysis technique using the Qiagen QIAamp Blood kit (Qiagen, Basel, Switzerland). The TLR4 Asp299Gly polymorphism was detected using a commercial assay from Genes4U (Genes4U, Winterthur, Switzerland) on a Light Cycler Real-Time PCR machine (Roche, Rotkreuz, Switzerland). The two polymorphisms at nucleotide positions T-1237C and G2848A of the TLR9 gene were detected by tetra-primer assays [22] . The assay used two primers complementary to unique sequences of TLR9 and two primers designed for the allele-specific amplification of the wild-type and the mutant alleles. The primers used to detect T-1237C were T-1237C up CCTGGGGATGCAGATAAAAGAT CAC and T-1237C low CTGTTCCCCTGAGTGCTC TCCA for TLR9 amplification and the C-allele GACTT GGGGGAGTTTC and T-allele TGTTCCCTCTGCC TGA-specific primers for allele specific amplification. The primers used to detect G2848A were G2848A up GAGGCAGATGGAGGGGAGAAGG and G2848A low GGACACTTGGCTGTGGATGTTGTT for TLR9 amplification and the A-allele ATTCACGGAGCTACCA and G-allele GGCCTCCAGTCGC-specific primers for allele specific amplification. The cycling conditions were 10 min at 941C, 15 cycles (first set) of 941C for 30 s, 621C for 30 s, 721C for 60 s, 27 cycles (second set) of 941C for 30 s, 401C for 30 s, 721C for 60 s, and a final extension of 7 min at 721C. The three polymorphisms C2104T, G2722C, and 3020insC in the NOD2 gene and the TNF-a G-308A polymorphism were analyzed as described earlier [19, 23] .
Statistical analysis
Statistical analysis was performed using Statistica (version 6; StatSoft Inc., 2300 East 14th Street Tulsa, Oklahoma, USA). Variables were compared using either w 2 test, Student's t-test, or Mann-Whitney U Test. To consider possible confounding effects, additional multiple regression analyses were performed on clinical expression of hemochromatosis and total body iron overload. Variables with uncertain influence (P > 0.1) were excluded during multiple regression analyses using a stepwise backward elimination procedure. The threshold of significance was defined with a two-sided a = 0.05.
Results
Patient characteristics
Ninety-nine patients with hereditary hemochromatosis were enrolled for this study -58 presented with typical clinical manifestation(s), 26 presented with elevated serum ferritin concentrations (without a typical clinical manifestation), and 15 were contacted on the basis of family screening. All these patients were homozygous for the G-845A (C282Y) mutation of the HFE gene and showed evidence of mild-to-severe iron overload by laboratory investigations. Of the 99 hemochromatosis patients, 13 (13%) were identified as heterozygous carriers of the TLR4 Asp299Gly polymorphism and 86 (87%) were TLR4 wild-type carriers. Hence, prevalence of the TLR4 polymorphism corresponded to an allele frequency of 6.5%, similar to values reported for Caucasian populations without hemochromatosis [24, 25] . Allele frequencies of TLR9 and NOD2 polymorphisms (data not shown) were also similar to values reported earlier for Caucasians [23, 26] . Table 1 shows that the baseline characteristics of the 99 hemochromatosis patients were well balanced between heterozygous carriers of the TLR4 Asp299Gly polymorphism and TLR4 wild-type carriers. There were no significant differences between the two study groups with regard to sex, age, body mass index, meat intake, or alcohol consumption assessed as habit patterns. This was true independent of whether all 99 hemochromatosis patients (Table 1) or only the 84 index patients (data not shown) were evaluated.
Clinical and biochemical manifestations
We considered hereditary hemochromatosis to be clinically expressed, if patients showed one or several clinical manifestations, such as liver disease, arthropathy of metacarpophalangeal joints, secondary diabetes mellitus, cardiopathy, or hypogonadism. Table 2 shows that, in the 99 hemochromatosis patients, prevalence of clinical expression was significantly higher in heterozygous carriers of the TLR4 Asp299Gly polymorphism (100%) than in TLR4 wild-type carriers (56%, P = 0.002). This result was based on higher prevalences of liver disease (92 vs. 45%, P = 0.002) and arthropathy of metacarpophalangeal joints (69 vs. 35%, P = 0.018) in carriers of the TLR4 Asp299Gly polymorphism as compared with TLR4 wild-type carriers. The further manifestations of hemochromatosis, that is, diabetes mellitus, cardiopathy, and hypogonadism, were rare and did not differ significantly between the two study groups.
Association of the TLR4 polymorphism and liver disease was significantly independent of whether evaluating liver fibrosis in histological examination, elevated ALT concentration at the time of diagnosis, or a combined score (Table 2 ). Histological analysis of liver tissue was performed in 52 of the 99 hemochromatosis patients. In this subgroup, all carriers of the TLR4 Asp299Gly polymorphism (100%) had liver fibrosis as compared with 52% of the TLR4 wild-type carriers (P = 0.002). This result agrees well with the observation that 91% of the TLR4 Asp299Gly carriers, but only 56% of the TLR4 wild-type carriers had elevated serum concentrations of ALT at the time of diagnosis (n = 95, P = 0.026).
To avoid a possible screening bias, the data were also analyzed considering only the 84 patients presenting as the first members of their families (index patients). Prevalence of clinical expression of hemochromatosis remained significantly higher in carriers of the TLR4 Asp299Gly polymorphism (100%) than in the TLR4 wildtype carriers (64%, P = 0.012). Differences remained significant as well with regard to expression of liver disease (P = 0.009), histologically documentated liver fibrosis (P = 0.030), and arthropathy of the metacarpophalangeal joints (P = 0.025; Table 2 ).
Parameters representing iron accumulation in the 99 hemochromatosis patients are shown in Table 3 . Serum ferritin concentration and total body iron overload did not differ significantly between carriers and noncarriers of the TLR4 Asp299Gly polymorphism. The same was true for the hepatic iron index determined in a subgroup of 29 hemochromatosis patients. It was obvious, however, that all three iron parameters were higher in carriers of the TLR4 polymorphism.
Evaluation of a possible influence of TLR9 and NOD2 polymorphisms on phenotypic expression of hereditary hemochromatosis are shown in Table 4 . The TLR9 and NOD2 polymorphisms were not significantly associated with the clinical expression and the parameters representing iron accumulation, respectively.
Possible confounding effects
Multiple regression analyses were performed to exclude possible confounding effects on the results of the study (Table 5 ). Clinical expression of hereditary hemochromatosis remained significantly associated with heterozygous TLR4 Asp299Gly polymorphism (P = 0.009), but did not correlate with the polymorphisms of TLR9 and NOD2 (P > 0.1). Clinical expression was moreover associated with total body iron accumulation (P < 0.0001) and study inclusion as an index patient (P = 0.010) -these associations are plausible and agree with our pathophysiological understanding of hemochromatosis. Total body iron overload was not significantly associated with the polymorphisms of TLR4, TLR9, or NOD2 (P > 0.1) but, in contrast, with a TNF-a G-308A polymorphism (P = 0.0008). Influences of sex, age, body mass index, meat, and alcohol intake did not reach statistical significance (P > 0.1) in either of the multiple regression analyses. These variables were, therefore, excluded during the stepwise regression analyses.
Discussion
Patients homozygous for the C282Y mutation of the HFE gene are predisposed to develop hemochromatotic organ damage on the basis of iron accumulation and iron toxicity in the tissues. However, the clinical penetrance of the homozygous HFE C282Y mutation is highly variable with clinical manifestations of hemochromatosis ranging from absent to severe [3] [4] [5] . Notably, in a small percentage of HFE C282Y homozygotes, no alteration of iron metabolism is detectable [27] . These observations point toward further genetic and/or environmental factors modifying phenotypic expression of hereditary hemochromatosis.
This study included 99 homozygous carriers of the HFE C282Y mutation with mild-to-severe iron overload. In these hemochromatosis patients, the presence and the extent of clinical expression were investigated as a function of the polymorphisms in TLR4, TLR9, and NOD2. These genes, known to be involved in cellular immune responses [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , are candidates to contribute to the inflammatory reaction underlying clinical hemochromatosis. Our results provide good evidence that TLR4 is involved in clinical expression of hereditary hemochromatosis: carriers of TLR4 Asp299Gly polymorphism had significantly more often liver disease and arthropathy of the metacarpophalangeal joints than noncarriers of this allele. Association of the TLR4 polymorphism and clinical expression of hemochromatosis remained significant in multiple regression analysis, and a possible screening bias was eliminated by evaluating exclusively the 84 patients presenting as the first members of their families (index patients). The finding is strengthened in that histological examination of liver tissue specimens showed a significant 
Values are numbers of patients (%); P values were calculated by Student's t-test or w 2 test.
a Portal fibrosis and/or septal/bridging fibrosis or cirrhosis in histological examination or, in patients without biopsy, elevated alanine transaminase at the time of diagnosis. association between liver fibrosis and the TLR4 polymorphism in the subgroup of 52 hemochromatosis patients undergoing liver biopsy. In contrast, the polymorphisms of TLR9 and NOD2 were not significantly associated with clinical expression of hereditary hemochromatosis.
Total body iron overload of the hemochromatosis patients did not differ significantly between carriers and noncarriers of the TLR4 Asp299Gly polymorphism. Multiple regression analysis confirmed the absence of such an association. It showed, however, a significant influence of a TNF-a G-308A polymorphism on total body iron overload. We reported earlier that TNF-a G-308A polymorphism modulates iron accumulation in patients with hereditary hemochromatosis [19] . Figure 1 provides an overview with regard to the influence of the TLR4 polymorphism and the TNF-a polymorphism on the number of clinical manifestations and total body iron overload in the 99 hemochromatosis patients. It is obvious from this figure that the TLR4 Asp299Gly polymorphism mainly correlates with clinical expression, whereas the TNF-a G-308A polymorphism is associated Variables remaining in the model are set in bold. TNF-α 308A allele:
Influence of toll-like receptors (TLR)4 896A > G polymorphism and tumor necrosis factor (TNF)-a G-308A polymorphism on the number of clinical manifestations (mean ± SEM) and total body iron overload (mean ± SEM) in 99 patients with hereditary hemochromatosis. Patients carrying the TLR4 896A > G polymorphism and patients carrying both these polymorphisms had significantly more clinical manifestations than those hemochromatosis patients carrying none of these polymorphisms; *P < 0.05 (Mann-Whitney U test). TLR9 T-1237C  TLR9 G2848A  NOD2 C2104T  NOD2 G2722C  NOD2 with total body iron overload. Carriers of both, the TLR4 and the TNF-a polymorphism showed the highest number of clinical manifestations and the highest total body iron overload. This suggests a synergistic effect of the two polymorphisms with regard to clinical expression of hemochromatosis. Furthermore, we have observed that the prevalence of the TNF-a G-308A polymorphism was significantly higher in the group of TLR4 Asp299Gly polymorphism carriers (46%) than in the group of TLR4 wild-type carriers (16%, P = 0.012). Concomitant presence of the TLR4 polymorphism and the TNF-a polymorphism might represent a special risk constellation for individuals carrying a homozygous C282Y mutation of the HFE gene.
This study did not investigate the pathophysiological mechanism by which the TLR4 Asp299Gly polymorphism influences clinical hemochromatosis. However, we do show that the TLR4 polymorphism worsens the clinical course of hemochromatosis without influencing iron accumulation. This lends support to the notion that TLR4 is involved in the inflammatory process underlying clinical hemochromatosis. This notion is in line with a recent publication reporting TLR4-dependent progression of liver fibrosis [28] . Our results are also in line with earlier investigations showing association of the TLR4 Asp299Gly polymorphism and inflammatory processes, such as septic infection, Crohn's disease, or sarcoidosis [14] [15] [16] [29] [30] [31] [32] . However, TLR4 might play a different pathophysiological role in the course of these diseases than in hemochromatosis because hereditary hemochromatosis goes along with altered cytokine expression, altered monocyte function, and altered phagocytosis [33] [34] [35] .
In conclusion, this study provides evidence that the heterozygous TLR4 Asp299Gly genotype modulates phenotypic disease expression in patients with hereditary hemochromatosis. The TLR4 polymorphism is shown not to influence iron accumulation, which suggests that TLR4 might rather be involved in the signalling of inflammatory processes arising from the toxic effects of accumulated iron in tissues and from the underlying inflammation in clinical hemochromatosis.
